Key insights
- Merck declared a $0.85 quarterly dividend for Q3 2026. Recent positive clinical trial results (TroFuse-005) and a positive opinion from the European Medicines Agency for Keytruda, combined with strategic financial moves (bond sale), suggest continued growth. This may positively influence investor sentiment towards Merck and the broader pharmaceutical sector.
RAHWAY, N.J. - Merck & Co. (NYSE:MRK) announced today that its Board of Directors declared a quarterly dividend of $0.85 per share of common stock for the third quarter of 2026, according to a press release statement.
The dividend will be paid on July 8, 2026, to shareholders of record at the close of business on June 15, 2026. Trading at $120.68, Merck shares have surged 63.5% over the past year and appear undervalued according to InvestingPro analysis, which offers deeper insights through its comprehensive Pro Research Report covering this and 1,400+ other US equities.
The pharmaceutical company is known as MSD outside of the United States and Canada.
In other recent news, Merck & Co. has been active with several significant developments. The company raised $6 billion through a bond sale to refinance its acquisition of Terns Pharmaceuticals, demonstrating its strategic financial management. Merck’s Phase 3 TroFuse-005 trial for its endometrial cancer drug, sacituzumab tirumotecan, met its primary endpoints, showing improved overall and progression-free survival in patients with advanced or recurrent endometrial cancer. Additionally, Merck is collaborating with Erasca Inc. on a clinical trial for Erasca’s pan-RAS molecular glue ERAS-0015 in combination with Merck’s KEYTRUDA for RAS-mutant solid tumors.
Merck also received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for the use of Keytruda in combination with Padcev for certain bladder cancer patients. This recommendation awaits further review by the European Commission. Furthermore, Merck was part of a roundtable discussion held by China’s commerce ministry with over 50 foreign pharmaceutical firms, including notable names like Sanofi and Novartis. These recent developments highlight Merck’s ongoing efforts in expanding its pharmaceutical portfolio and strengthening its global presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.